Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) announced today that the company has
\nentered into a license agreement regarding the development and commercialization rights for the
\nantifungal agent fosravuconazole in the Asia\/Oceania region* with Sato Pharmaceutical Co., Ltd.
\n(Headquarters: Tokyo, \u201cSato Pharma\u201d). Under this agreement, Eisai exclusively licenses the intellectual
\nproperty rights of fosravuconazole in the given countries\/regions to Sato Pharma.<\/p>\n
Ravuconazole, the active ingredient of fosravuconazole, is an antifungal agent discovered and developed
\nby Eisai. Fosravuconazole is a prodrug of ravuconazole, which improves its solubility and bioavailability.
\nIn Japan, Seren Pharma (Headquarters: Tokyo) and Sato Pharma have developed fosravuconazole based
\non the exclusive rights to develop, commercialize, and sublicense granted by Eisai. The treatment has
\nbeen marketed by Sato Pharma as the oral antifungal agent Nailin\u00ae for the indication of \u201conychomycosis\u201d
\nsince July 2018, which Eisai is co-promoting.<\/p>\n
Under the terms of the agreement, Eisai will receive a contractual upfront payment, and the rights to receive
\nregulatory milestone payments and royalties based on sales over a certain period. Eisai will retain
\ndevelopment and commercialization rights related to mycetoma, a neglected tropical disease, and its
\nassociated conditions, as these are excluded from the licensing.<\/p>\n
Upon the conclusion of this agreement, Eisai hopes to maximize the value of fosravuconazole in the
\nAsia\/Oceania region, ensuring the earliest possible contribution to patients in need of the medicine.<\/p>\n
*10 ASEAN nations, Australia, New Zealand, South Korea, and Taiwan<\/p>\n","protected":false},"excerpt":{"rendered":"
Eisai Co., Ltd. announced today that the company has entered into a license agreement regarding the development and commercialization rights for the antifungal agent fosravuconazole in the Asia\/Oceania region with Sato Pharmaceutical Co., Ltd.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28,9],"tags":[],"class_list":["post-7916","post","type-post","status-publish","format-standard","hentry","category-news-en","category-undefined-en"],"_links":{"self":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/7916"}],"collection":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/comments?post=7916"}],"version-history":[{"count":2,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/7916\/revisions"}],"predecessor-version":[{"id":7918,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/7916\/revisions\/7918"}],"wp:attachment":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/media?parent=7916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/categories?post=7916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/tags?post=7916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}